The Multiple Myeloma Hub virtual symposium held on March 11, 2024 entitled “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023” closed with a panel Q&A session with live audience participation.
Our panellists shared their perspectives on key topics including health-related quality of life in patients treated with bispecific antibodies, highlighting the impact of reduced dosing frequencies, as well as subcutaneous versus intravenous administration, on the patient experience.
Негізгі бет Symposium | Q&A session
Пікірлер